Page last updated: 2024-08-26

catalpol and regorafenib

catalpol has been researched along with regorafenib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abd-Alhaseeb, MM; El-Hanboshy, SM; Helmy, MW	1

Other Studies

1 other study(ies) available for catalpol and regorafenib

Article	Year
Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways. Molecular biology reports, 2021, Volume: 48, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Iridoid Glucosides; Liver Neoplasms; NF-kappa B; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2021

Article

Year

Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.

Molecular biology reports, 2021, Volume: 48, Issue:11

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Hep G2 Cells; Humans; Iridoid Glucosides; Liver Neoplasms; NF-kappa B; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2021